Zobrazeno 1 - 10
of 143
pro vyhledávání: '"Tarek Sahmoud"'
Autor:
Sherene Loi, Stefan Michiels, Jose Baselga, John M S Bartlett, Sandeep K Singhal, Vicky S Sabine, Andrew H Sims, Tarek Sahmoud, J Michael Dixon, Martine J Piccart, Christos Sotiriou
Publikováno v:
PLoS ONE, Vol 14, Iss 4, p e0216175 (2019)
[This corrects the article DOI: 10.1371/journal.pone.0053292.].
Externí odkaz:
https://doaj.org/article/d71c1eb6584e47cfbf6051eab8cecf7c
Autor:
Sherene Loi, Stefan Michiels, Jose Baselga, John M S Bartlett, Sandeep K Singhal, Vicky S Sabine, Andrew H Sims, Tarek Sahmoud, J Michael Dixon, Martine J Piccart, Christos Sotiriou
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e53292 (2013)
The phosphatidylinositol 3' kinase (PI3K) pathway is commonly activated in breast cancer and aberrations such as PI3K mutations are common. Recent exciting clinical trial results in advanced estrogen receptor-positive (ER) breast cancer support mTOR
Externí odkaz:
https://doaj.org/article/6b52976f3af14e91b6fddd339081c482
Autor:
Craig Furman, Xiaoling Puyang, Zhaojie Zhang, Zhenhua J. Wu, Deepti Banka, Kiran B. Aithal, Lee A. Albacker, Ming-Hong Hao, Sean Irwin, Amy Kim, Meagan Montesion, Alyssa D. Moriarty, Karthikeyan Murugesan, Tuong-Vi Nguyen, Victoria Rimkunas, Tarek Sahmoud, Michael J. Wick, Shihua Yao, Xun Zhang, Hao Zeng, Frédéric H. Vaillancourt, David M. Bolduc, Nicholas Larsen, Guo Zhu Zheng, Sudeep Prajapati, Ping Zhu, Manav Korpal
Publikováno v:
Molecular Cancer Therapeutics. 21:890-902
Nearly 30% of patients with relapsed breast cancer present activating mutations in estrogen receptor alpha (ERα) that confer partial resistance to existing endocrine-based therapies. We previously reported the development of H3B-5942, a covalent ER
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36d847689ba41601cee0daf9b3b85720
https://doi.org/10.1158/1535-7163.mct-21-0378
https://doi.org/10.1158/1535-7163.mct-21-0378
Autor:
Manav Korpal, Ping Zhu, Sudeep Prajapati, Guo Zhu Zheng, Nicholas Larsen, David M. Bolduc, Frédéric H. Vaillancourt, Hao Zeng, Xun Zhang, Shihua Yao, Michael J. Wick, Tarek Sahmoud, Victoria Rimkunas, Tuong-Vi Nguyen, Karthikeyan Murugesan, Alyssa D. Moriarty, Meagan Montesion, Amy Kim, Sean Irwin, Ming-Hong Hao, Lee A. Albacker, Kiran B. Aithal, Deepti Banka, Zhenhua J. Wu, Zhaojie Zhang, Xiaoling Puyang, Craig Furman
Supplementary Figure from Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13142bfee94cfe0c7131be792af46c56
https://doi.org/10.1158/1535-7163.22522680
https://doi.org/10.1158/1535-7163.22522680
Autor:
Manav Korpal, Ping Zhu, Sudeep Prajapati, Guo Zhu Zheng, Nicholas Larsen, David M. Bolduc, Frédéric H. Vaillancourt, Hao Zeng, Xun Zhang, Shihua Yao, Michael J. Wick, Tarek Sahmoud, Victoria Rimkunas, Tuong-Vi Nguyen, Karthikeyan Murugesan, Alyssa D. Moriarty, Meagan Montesion, Amy Kim, Sean Irwin, Ming-Hong Hao, Lee A. Albacker, Kiran B. Aithal, Deepti Banka, Zhenhua J. Wu, Zhaojie Zhang, Xiaoling Puyang, Craig Furman
Supplementary Data from Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f3c5a51d03835d7dd69df06b71625f3
https://doi.org/10.1158/1535-7163.22522686.v1
https://doi.org/10.1158/1535-7163.22522686.v1
Autor:
Erika P Hamilton, Judy S Wang, Timothy Pluard, Aki Morikawa, E Claire Dees, Robert H Jones, Barbara Haley, Anne Armstrong, Adam L Cohen, Pamela Munster, Gail S Wright, Fadi Kayali, Lisa Cantagallo, Manav Korpal, Jenny Long, Jianjun Xiao, Benoit Destenaves, Lei Gao, Tarek Sahmoud, Antonio Gualberto, Dejan Juric
Publikováno v:
Cancer Research. 82:P1-17
Purpose: H3B-6545, a novel Selective ERα Covalent Antagonist (SERCA), inactivates both and wild-type and mutant ERα by targeting cysteine 530 and enforcing antagonist conformation. H3B-6545 demonstrated preclinical high activity in breast cancer mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2223d1a108001e2ae8d527a4f9ed90d5
https://doi.org/10.1158/1538-7445.sabcs21-p1-17-10
https://doi.org/10.1158/1538-7445.sabcs21-p1-17-10
Autor:
Stephen Johnston, Timothy J Pluard, Judy S Wang, Erika P Hamilton, Dejan Juric, Catherine R Scholz, Elizabeth Hnitecki, Sara Dar, Lei Gao, Lisa Cantagallo, Manav Korpal, Jianjun Alan Xiao, Lihua Yu, Tarek Sahmoud, Antonio Gualberto
Publikováno v:
Cancer Research. 82:P1-17
Background: H3B-6545, a novel Selective ERα Covalent Antagonist (SERCA), inactivates both mutant and wild-type ERα by targeting cysteine 530 and enforcing antagonist conformation. It demonstrated a manageable safety profile and single-agent antitum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a929ce0d9e99e2c19e565df11cf79fd9
https://doi.org/10.1158/1538-7445.sabcs21-p1-17-03
https://doi.org/10.1158/1538-7445.sabcs21-p1-17-03
Autor:
Sailaja Kamaraju, Amy Fowler, Chung Yee Cheng, Lubna N Chaudhary, John Burfeind, Janet Retseck, Amye J Tevaarwerk, Mark Burkard, Elisavet Paplomata, Amanda M Parkes, Julie M Jorns, Sergey Tarima, Douglas Yee, Hallgeir Rui, Carol Lange, Tarek Sahmoud, Kari B Wisinski
Publikováno v:
Cancer Research. 82:OT2-16
Background Antiprogestins, including selective progesterone receptor (PgR) modulators (SPRMs) that act as PgR antagonists, are a promising class of therapeutics for overcoming endocrine resistance including in patients who develop activating estrogen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33f61bf246216673879a044679242c2e
https://doi.org/10.1158/1538-7445.sabcs21-ot2-16-01
https://doi.org/10.1158/1538-7445.sabcs21-ot2-16-01
Autor:
Timothy J. Pluard, Ziad Husseiin, Sanae Yasuda, Erika Hamilton, Tarek Sahmoud, Oneeb Majid, Jianjun Alan Xiao, Dejan Juric, Lisa Cantagallo, Antonio Gualberto
Publikováno v:
Cancer Research. 81:PS12-15
RATIONALE: Addition of CDK 4/6 inhibitors to endocrine therapy has become standard for patients (pts) with ER+ and HER2- BC with improvements in overall survival. However, acquired resistance to front-line therapy is inevitable, and response to later
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dbc6eac292b6dd7f7708e6d446c833cb
https://doi.org/10.1158/1538-7445.sabcs20-ps12-15
https://doi.org/10.1158/1538-7445.sabcs20-ps12-15
Autor:
Sailaja Kamaraju, Amy Fowler, Lubna N. Chaudhary, Mark Burkard, Thomas Giever, Robert N Hegeman, Michele Pipp-Dahm, Yee Chung Cheng, Carol Lange, Julie M. Jorns, Amy Stella, Nauman Siddiqui, Luke Zurbriggen, Saurabh Rajguru, Sergey Tarima, Deepika Sriram, Janet Retseck, Hallgeir Rui, Tarek Sahmoud, Kari B. Wisinski
Publikováno v:
Cancer Research. 83:OT2-01
Background Antiprogestins, including selective progesterone receptor (PgR) modulators (SPRMs) that act as PgR antagonists, are a promising class of therapeutics for overcoming endocrine resistance including in patients who develop activating estrogen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdb5ae297d29a385c35e767bc9e3e973
https://doi.org/10.1158/1538-7445.sabcs22-ot2-01-02
https://doi.org/10.1158/1538-7445.sabcs22-ot2-01-02